Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Efficacy of anipamil, a phenylalkylamine calcium antagonist, in treatment of angina pectoris.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  1. Exploration of physiological and pathophysiological implications of miRNA-143 and miRNA-145 in cerebral arteries

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Antiarrhythmic Effects of Combining Dofetilide and Ranolazine in a Model of Acutely Induced Atrial Fibrillation in Horses

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Potentiated adrenomedullin-induced vasorelaxation during hypoxia in organ cultured porcine coronary arteries

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Autonomic dysfunction and impaired cerebral autoregulation in cirrhosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. C-reactive protein, heart rate variability and prognosis in community subjects with no apparent heart disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
To evaluate the efficacy of anipamil, a phenylalkylamine calcium antagonist, in treatment of stable angina pectoris, we performed a randomized, double blind placebo-controlled, cross-over study. Inclusion criteria were (a) stable angina pectoris for at least 2 months, (b) an exercise test with > or = 0.1-mV horizontal or downsloping ST-segment depression limited by angina, and (c) at least 10 attacks of angina pectoris in a single-blind 3-week run-in period. Nineteen patients were randomized to enter the study. In 3-week periods, they received either anipamil 80 mg once daily (o.d.), anipamil 160 mg o.d., or placebo. At the end of each period, an exercise test was performed. The number of angina pectoris attacks was significantly reduced during treatment with anipamil 80 mg (p < 0.05) and anipamil 160 mg (p < 0.001) as compared with placebo. Glycerol nitrate consumption was significantly reduced during treatment with anipamil 80 mg (p < 0.01) and 160 mg (p < 0.001) as compared with placebo. During exercise testing, the load (W) at start of angina was significantly increased during treatment with anipamil 80 mg (p < 0.01) and 160 mg (p < 0.05) as compared with placebo. Heart rate (HR) at 0.1 mV ST-segment depression was increased during treatment with anipamil 80 mg (p < 0.001). Few adverse events were reported.
Bidragets oversatte titelEfficacy of anipamil, a phenylalkylamine calcium antagonist, in treatment of angina pectoris.
OriginalsprogEngelsk
TidsskriftJournal of Cardiovascular Pharmacology
Vol/bind24
Udgave nummer5
Sider (fra-til)841-845
Antal sider5
ISSN0160-2446
StatusUdgivet - 1994

ID: 32555223